Filing Details
- Accession Number:
- 0001209191-15-032482
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-03 19:11:27
- Reporting Period:
- 2015-04-01
- Filing Date:
- 2015-04-03
- Accepted Time:
- 2015-04-03 19:11:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1051411 | T Erle Mast | C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301 | Executive Vp And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-04-01 | 1,260 | $70.52 | 158,323 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-04-01 | 1,540 | $71.57 | 156,783 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-04-01 | 100 | $72.65 | 156,683 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-04-01 | 100 | $74.31 | 156,583 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $70.10 to $70.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $71.10 to $71.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.